The McKay Institute

The McKay Institute targets growth and venture-stage companies within the oncology ecosystem. Its investment thesis centers on community oncology — the independent cancer-care practices that treat the majority of US patients outside academic hospitals. The firm's sector reach includes healthcare services, digital health, practice-management software, and AI/ML applications deployed in clinical cancer-care workflows.

The firm operates as a specialized private equity platform with offices in New York, Boston, and Nashville. It is not structured as a family office but as an asset manager focused on a single therapeutic area. The firm's website at tnoncology.com reflects this oncology-specific mandate, though the ownership and governance structure remain private.

Named principals and the firm's investment committee composition are not publicly disclosed. The firm maintains a low public profile with no LinkedIn page and limited web presence as of mid-2026, which is consistent with a closely held investment vehicle that sources deals through clinical and operational networks rather than public marketing.

Community oncology practices face distinct economic pressures: reimbursement complexity, drug-pricing volatility, and consolidation by hospital systems. The McKay Institute appears to invest in companies that provide the operational infrastructure, technology, and services that help these independent practices remain financially viable outside large health systems.

The firm's investment structure — whether it operates via direct co-investments, SPVs, or committed fund vehicles — has not been publicly described. Based on the firm's narrow oncology mandate, direct or co-investment structures are the most common vehicles for thesis-driven specialist platforms of this type.